Juvenile parkinsonism: A patient with possible primary striatal dysfunction
β Scribed by Sakkubai Naidu; Dr Leslie I. Wolfson; Nansie S. Sharpless
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 310 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
A 15βyearβold boy who initially manifested dystonic features and later developed classic parkinsonism is described. Cerebrospinal fluid homovanillic acid levels were normal or slightly elevated both before and after administration of probenecid. The patient responded favorably to treatment with levodopa and carbidopa. The normal or slightly elevated cerebrospinal fluid homovanillic acid levels contrast with the low levels usually seen in adult parkinsonian patients. The data on this patient suggest direct neostriatal involvement rather than depletion of neurons of the substantia nigra. Juvenile parkinsonism may have at least two distinct pathological forms, but they have similar clinical features and a similar response to treatment.
π SIMILAR VOLUMES
We describe a 16-year-old girl with systemic-onset juvenile arthritis who presented with pulmonary hypertension, without evidence of pleural or parenchymal involvement of the lung, pulmonary vasculitis, or immune deposition in the pulmonary vasculature. Pleuropulmonary involvement occurs occasionall
## Abstract Xβlinked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by a mutation in the Bruton agammaglobulinemia tyrosine kinase gene that results in severe Bβcell deficiency. So far, neurological complications of XLA have been primarily related to acute and/or chronic cen
Background: Pathological gambling may occur in Parkinson's disease (PD) as a complication of dopaminergic therapy. Neuroimaging studies have suggested an abnormal dopamine transmission within the reward system, but the changes in the neural network characterizing PD patients with pathological gambli
## Abstract We used [^11^C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D~2~ receptor binding in nine patients with Parkinson's disease (PD) at an early drugβnaive stage and 3β5 years later, when motor fluctuations had appeared in seven of them